25.2 C
New York
Tuesday, May 19, 2026

FDA approves vepdegestrant NDA for ESR1-mutated breast cancer


FDA accepts vepdegestrant NDA for ESR1-mutated breast cancer

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles